Active ingredientIpragliflozinCat. No. P-I069-001CAS 761423-87-4Family · Pharmaceutical analytical standards
Ipragliflozin
An inhibitor of the sodium-glucose cotransporter SGLT2, which stops the kidneys from reabsorbing sugar so that it is excreted in the urine; approved in Japan in January 2014 for type 2 diabetes, it was the first drug of its class sold in the country. This family brings together the active ingredient, labelled standards and other impurities.
Did you know?Its molecule joins a sugar ring, glucitol, to a group carrying a benzothiophene, a double ring with a sulphur atom, and a fluorine atom.
Go to the active ingredient →Active ingredientIpragliflozinCat. No. P-I069-001CAS 761423-87-4
Isotopically labelledIpragliflozin-13C6Cat. No. P-I069-003CAS 2743031-48-1
Isotopically labelledIpragliflozin-d3Cat. No. P-I069-004
Isotopically labelledIpragliflozin-d5Cat. No. P-I069-005
ImpurityIpragliflozin Impurity 1Cat. No. P-I069-006
ImpurityIpragliflozin Impurity 2Cat. No. P-I069-007
ImpurityIpragliflozin Impurity 3Cat. No. P-I069-008CAS 1922933-61-6
ImpurityIpragliflozin Impurity 4Cat. No. P-I069-009No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.